Abstract:Nonalcoholic fatty liver disease (NAFLD) is featured with excessive hepatic lipid accumulation and its global prevalence is soaring. Nonalcoholic steatohepatitis (NASH), the severe systemic inflammatory subtype of NAFLD, is tightly associated with metabolic comorbidities, and the hepatocytes manifest severe inflammation and ballooning. Currently the therapeutic options for treating NASH are limited. Potent small molecules specifically intervene with the signaling pathways that promote pathogenesis of NASH. Nevertheless they have obvious adverse effects and show long-term ineffectiveness in clinical trials. It poses the fundamental question to efficiently and safely inhibit the pathogenic processes. Targeted protein degradation (TPD) belongs to the direct degradation strategies and is a burgeoning strategy. It utilizes the small molecules to bind to the target proteins and recruit the endogenous proteasome, lysosome and autophagosome-mediated degradation machineries. They effectively and specifically degrade the target proteins. It has exhibited promising therapeutic effects in treatment of cancer, neurodegenerative diseases and other diseases in a catalytic manner at low doses. We critically discuss the principles of multiple direct degradation strategies, especially PROTAC and ATTEC. We extensively analyze their emerging application in degradation of excessive pathogenic proteins and lipid droplets, which promote the progression of NASH. Moreover, we discuss the opposite strategy that utilizes the small molecules to recruit deubiquinases to stabilize the NASH/MASH-suppressing proteins. Their advantages, limitations, as well as the solutions to address the limitations have been analyzed. In summary, the innovative direct degradation strategies provide new insights into design of next-generation therapeutics to combat NASH with optimal safety paradigm and efficiency.

Direct degradation and stabilization of proteins: New horizons in treatment of nonalcoholic steatohepatitis

Drug targets regulate systemic metabolism and provide new horizons to treat nonalcoholic steatohepatitis

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Recent advances in targeted protein degraders as potential therapeutic agents

Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques

Advancing targeted protein degradation for metabolic diseases therapy

Targeted Protein Degradation Technology and Nanomedicine: Powerful Allies Against Cancer

Targeted protein degradation in drug development: Recent advances and future challenges

Current, emerging, and potential therapies for non-alcoholic steatohepatitis

Novel approaches to targeted protein degradation technologies in drug discovery

Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance

Progress of small molecules for targeted protein degradation: PROTACs and other technologies

Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins

Targeted protein degradation: mechanisms, strategies and application

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies

Targeted protein degradation in cancers: Orthodox PROTACs and beyond

From PROTAC to TPD: Advances and Opportunities in Targeted Protein Degradation

Molecular Mechanisms and New Treatment Strategies for Non-Alcoholic Steatohepatitis (NASH)

Discovery of NAFLD-Improving Agents by Promoting the Degradation of Keap1.

Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives

Depletion of Activated Hepatic Stellate Cells and Capillarized Liver Sinusoidal Endothelial Cells Using a Rationally Designed Protein for Nonalcoholic Steatohepatitis and Alcoholic Hepatitis Treatment